NO20062765L - Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse - Google Patents

Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse

Info

Publication number: NO20062765L
Authority: NO; Norway
Prior art keywords: carrier; amino acid; processes; preparation; acid residues
Prior art date: 2003-12-17

Application number

NO20062765A

Other languages

English (en)

Norwegian (no)

Inventor

Krishna A Prasad

Rasappa G Arumugham

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-17

Filing date

2006-06-13

Publication date

2006-09-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34700143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062765(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-13 Application filed by Wyeth Corp filed Critical Wyeth Corp

2006-09-14 Publication of NO20062765L publication Critical patent/NO20062765L/no

Links

230000002163 immunogen Effects 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
125000000539 amino acid group Chemical group 0.000 abstract 2
125000000524 functional group Chemical group 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Mycology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Inorganic Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

NO20062765A 2003-12-17 2006-06-13 Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse NO20062765L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53048103P	2003-12-17	2003-12-17
PCT/US2004/044093 WO2005058941A2 (en)	2003-12-17	2004-12-17	Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME

Publications (1)

Publication Number	Publication Date
NO20062765L true NO20062765L (no)	2006-09-14

Family

ID=34700143

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062765A NO20062765L (no)	2003-12-17	2006-06-13	Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse

Country Status (26)

Country	Link
US (5)	US8227403B2 (ja)
EP (4)	EP2336147B1 (ja)
JP (1)	JP4696079B2 (ja)
KR (2)	KR101201120B1 (ja)
CN (1)	CN1934127B (ja)
AR (1)	AR047062A1 (ja)
AU (2)	AU2004299512B2 (ja)
BR (1)	BRPI0417689A8 (ja)
CA (1)	CA2549552A1 (ja)
CR (1)	CR8445A (ja)
DK (1)	DK2336147T3 (ja)
EA (2)	EA009559B1 (ja)
EC (1)	ECSP066646A (ja)
ES (1)	ES2474173T3 (ja)
HK (2)	HK1104826A1 (ja)
IL (2)	IL176250A (ja)
MX (1)	MXPA06006821A (ja)
MY (1)	MY144231A (ja)
NO (1)	NO20062765L (ja)
PL (1)	PL2336147T3 (ja)
PT (1)	PT2336147E (ja)
SG (2)	SG182189A1 (ja)
SI (1)	SI2336147T1 (ja)
TW (2)	TWI357414B (ja)
UA (1)	UA84728C2 (ja)
WO (1)	WO2005058941A2 (ja)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) *	1998-04-07	2005-03-17	Neuralab Ltd	Prevention and treatment of amyloidogenic disease
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
NZ567324A (en) *	2003-02-01	2009-08-28	Wyeth Corp	Active immunization to generate antibodies to soluble A-beta
TWI306458B (en) *	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
AR047062A1 (es)	2003-12-17	2006-01-04	Wyeth Corp	Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
EA012984B1 (ru) *	2003-12-17	2010-02-26	Вайет	Конъюгаты иммуногенных пептидных носителей и способы их получения
JP2007522119A (ja) *	2004-01-28	2007-08-09	キュリックスエーピーエス	アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
WO2006041934A2 (en) *	2004-10-05	2006-04-20	Neuralab Limited	Methods and compositions for improving recombinant protein production
CA2590337C (en)	2004-12-15	2017-07-11	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) *	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
TW200740839A (en) *	2005-06-17	2007-11-01	Wyeth Corp	Methods of purifying Fc region containing proteins
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
EP2046833B9 (en)	2006-07-14	2014-02-19	AC Immune S.A.	Humanized antibody against amyloid beta
US8652782B2 (en)	2006-09-12	2014-02-18	Longhorn Vaccines & Diagnostics, Llc	Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en)	2006-09-12	2016-11-01	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8084443B2 (en)	2007-10-01	2011-12-27	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection and transport system and methods of use
US8080645B2 (en)	2007-10-01	2011-12-20	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection/transport compositions and methods
US8097419B2 (en)	2006-09-12	2012-01-17	Longhorn Vaccines & Diagnostics Llc	Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
WO2008124646A2 (en) *	2007-04-06	2008-10-16	The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services	Use of amyloid proteins as vaccine scaffolds
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
TR201802286T4 (tr) *	2007-04-20	2018-03-21	The Chemo Sero Therapeutic Res Institute	Peptidle bağışıklık yanıtının arttırılması için yöntem.
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
ES2498040T3 (es)	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
US9683256B2 (en)	2007-10-01	2017-06-20	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system
US11041215B2 (en)	2007-08-24	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP3058954B1 (en)	2007-08-27	2017-03-01	Longhorn Vaccines and Diagnostics, LLC	Immunogenic compositions and methods
US10004799B2 (en)	2007-08-27	2018-06-26	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
US11041216B2 (en)	2007-10-01	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2701793C (en)	2007-10-05	2017-04-25	Genentech, Inc.	Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
ITNA20080006A1 (it) *	2008-01-28	2009-07-29	Consiglio Nazionale Ricerche	Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp
CN102256620B (zh) *	2008-08-07	2016-11-16	莫西亚药物公司	用于治疗阿尔茨海默氏病的免疫治疗组合物
KR101640147B1 (ko) *	2008-10-16	2016-07-18	잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼	변성된 아밀로이드 베타 펩티드
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
DE102008037564A1 (de) *	2008-11-19	2010-05-20	Forschungszentrum Jülich GmbH	Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
AR080446A1 (es)	2010-03-03	2012-04-11	Boehringer Ingelheim Int	Polipeptidos de union a a-beta (beta amiloide)
MX341369B (es)	2010-07-30	2016-08-17	Genentech Inc *	Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
GB201101331D0 (en) *	2011-01-26	2011-03-09	Glaxosmithkline Biolog Sa	Compositions and uses
US20120321694A1 (en) *	2010-10-27	2012-12-20	Daniel Larocque	Compositions and uses
CN102279269A (zh) *	2011-04-12	2011-12-14	王贤俊	胱抑素c检测剂盒的制备方法
EP2716661B1 (en) *	2011-06-01	2018-03-07	Xiamen University	Fusion protein comprising diphtheria toxin non-toxic mutant crm197 or fragment thereof
US8906382B2 (en) *	2011-07-19	2014-12-09	New York University	Method for treating amyloid disease
GB201113570D0 (en) *	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
WO2013021353A1 (en) *	2011-08-11	2013-02-14	Bar-Ilan University	Surface modified proteinaceous spherical particles and uses thereof
KR102129220B1 (ko) *	2011-09-23	2020-07-02	에이씨 이뮨 에스.에이.	백신 요법
CN104203272A (zh)	2012-01-26	2014-12-10	长角牛疫苗和诊断有限责任公司	复合抗原序列及疫苗
DK2668959T3 (en) *	2012-05-31	2015-01-26	Innavirvax	Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
KR101451797B1 (ko) *	2012-11-07	2014-10-16	가천대학교 산학협력단	멀티머-형성 폴리펩타이드의 멀티머 정량분석을 위한 표준 단백질 복합체
CA2919835A1 (en) *	2013-07-31	2015-02-05	Board Of Trustees Of The University Of Arkansas	Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
EP2870974A1 (en) *	2013-11-08	2015-05-13	Novartis AG	Salmonella conjugate vaccines
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN104069504B (zh)	2014-05-11	2019-09-24	江苏康泰生物医学技术有限公司	一种增强多糖蛋白结合物免疫原性的方法
EP3156423A4 (en) *	2014-06-11	2018-04-11	Riken	Multiplex alloantigenic peptide
US9107906B1 (en)	2014-10-28	2015-08-18	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
EP3294448A4 (en)	2015-05-14	2018-12-12	Longhorn Vaccines and Diagnostics, LLC	Rapid methods for the extraction of nucleic acids from biological samples
BR112019001115A2 (pt) *	2016-07-21	2019-06-25	Vac4All Pte Ltd	proteínas de biofusão como vacinas anti-malária
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2019169120A1 (en)	2018-02-28	2019-09-06	University Of Washington	Self-asssembling nanostructure vaccines
WO2020257315A1 (en) *	2019-06-18	2020-12-24	Citranvi Biosciences, Llc	Multiple antigen protein displayed adjuvant systems
KR20230107621A (ko)	2020-11-13	2023-07-17	아이코사백스, 인크.	메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
US11571481B2 (en)	2020-12-21	2023-02-07	Cornell University	Peptide-linked drug delivery system
CN114137203A (zh) *	2021-10-21	2022-03-04	广州万孚生物技术股份有限公司	抗原与碱性磷酸酶结合物的制备方法
WO2023225562A1 (en)	2022-05-17	2023-11-23	Icosavax, Inc.	Multivalent vaccine for paramyxoviruses and uses thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2982084A (en) *	1957-05-29	1961-05-02	Ebauches Sa	Alarm device
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4673574A (en)	1981-08-31	1987-06-16	Anderson Porter W	Immunogenic conjugates
US4902506A (en)	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
US5360897A (en)	1981-08-31	1994-11-01	The University Of Rochester	Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5126131A (en)	1983-01-24	1992-06-30	The Johns Hopkins University	Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US4882317A (en) *	1984-05-10	1989-11-21	Merck & Co., Inc.	Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5078996A (en)	1985-08-16	1992-01-07	Immunex Corporation	Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US5245015A (en) *	1991-04-26	1993-09-14	Tanox Biosystems, Inc.	Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5089603A (en) *	1989-06-21	1992-02-18	Tanox Biosystems, Inc.	Antigenic epitopes present on membrane-bound but not secreted iga
US5785973A (en)	1988-02-01	1998-07-28	Praxis Biologics, Inc.	Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5192540A (en)	1988-04-19	1993-03-09	American Cyanamid Company	Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
DE68907045T2 (de)	1989-01-17	1993-12-02	Eniricerche Spa	Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CA2084307A1 (en)	1990-06-01	1991-12-02	Cetus Oncology Corporation	Compositions and methods for identifying biologically active molecules
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
CA2059692C (en)	1991-01-28	2004-11-16	Peter J. Kniskern	Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en)	1991-05-02	2005-06-19	Amgen Inc	Recombinant dna-derived cholera toxin subunit analogs
DE69217497T2 (de)	1991-09-18	1997-06-12	Affymax Tech Nv	Verfahren zur synthese der verschiedenen sammlungen von oligomeren
WO1993013302A1 (de)	1991-12-23	1993-07-08	Michael Zoche	Motor mit einer vorrichtung zur entölung
KR950700081A (ko) *	1992-02-11	1995-01-16	W 로우 죤	이중 캐리어 면역원성 구성물
WO1994008051A1 (en)	1992-10-01	1994-04-14	The Trustees Of Columbia University In The City Of New York	Complex combinatorial chemical libraries encoded with tags
ES2231770T3 (es)	1993-03-05	2005-05-16	Wyeth Holdings Corporation	Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
JP3926839B2 (ja)	1993-09-14	2007-06-06	エピミューン，インコーポレイティド	万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
AU703472B2 (en)	1993-11-02	1999-03-25	Affymax Technologies N.V.	Synthesizing and screening molecular diversity
US5571515A (en)	1994-04-18	1996-11-05	The Wistar Institute Of Anatomy & Biology	Compositions and methods for use of IL-12 as an adjuvant
EP0758313A4 (en)	1994-05-06	1999-09-15	Pharmacopeia Inc	COMBINATORIAL LIBRARY OF DIHYDROBENZOPYRANES
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
IL115933A0 (en)	1995-11-09	1996-01-31	Oramir Semiconductor Ltd	Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls
WO1997017614A1 (en)	1995-11-10	1997-05-15	Elan Corporation, Plc	Peptides which enhance transport across tissues and methods of identifying and using the same
EP0958364A4 (en)	1996-10-23	2001-10-31	Univ Pennsylvania	IMMUNOTHERAPY AND IMPROVED Vaccines
US6962984B2 (en) *	1996-12-05	2005-11-08	Nihon University	IgA nephropathy-related DNA
PT848011E (pt)	1996-12-16	2001-08-30	Staat Nl Verteg Door Min Welzi	Metodo para acoplar polisacaridos a proteinas
US5877220A (en)	1997-03-06	1999-03-02	Genta, Incorporated	Amide-based oligomeric cationic lipids
US20020086847A1 (en)	1997-04-09	2002-07-04	Mindset Biopharmaceuticals (Usa)	Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6113918A (en)	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6743427B1 (en)	1997-12-02	2004-06-01	Neuralab Limited	Prevention and treatment of amyloidogenic disease
GB2333706A (en)	1998-02-02	1999-08-04	Merck & Co Inc	Method for increasing muscle mass in animals
CA2322160C (en)	1998-02-27	2013-01-29	The Trustees Of The University Of Pennsylvania	Vaccines, immunotherapeutics and methods for using the same
CA2264970A1 (en)	1998-03-10	1999-09-10	American Cyanamid Company	Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6645503B1 (en) *	1998-03-10	2003-11-11	Wyeth Holdings Corporation	Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US20050059591A1 (en)	1998-04-07	2005-03-17	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20050059802A1 (en)	1998-04-07	2005-03-17	Neuralab Ltd	Prevention and treatment of amyloidogenic disease
ES2293735T3 (es)	1998-09-30	2008-03-16	Wyeth Holdings Corporation	Holotoxina del colera mutante como coadyuvante.
US6245015B1 (en) *	1998-12-07	2001-06-12	General Electric Company	Photosonic diffusion wave-based tumor detector
EP1156825A2 (en) *	1999-02-25	2001-11-28	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
US6945135B1 (en)	1999-09-09	2005-09-20	L. H. Thomson Company, Inc.	Bicycle stem for enlarged handlebar portions and associated methods
GB9925559D0 (en) *	1999-10-28	1999-12-29	Smithkline Beecham Biolog	Novel method
WO2001039796A2 (en) *	1999-11-29	2001-06-07	Neurochem Inc.	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
DE60114157T2 (de)	2000-02-21	2006-06-29	Pharmexa A/S	Verfahren zur herabregulierung von amyloid
US20030190322A1 (en)	2000-03-31	2003-10-09	Peter Kaastrup	Immunostimulating properties of a fragment of tgf-beta
WO2001090182A2 (en) *	2000-05-22	2001-11-29	New York University	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
JP2004509846A (ja)	2000-06-02	2004-04-02	メルク　エンド　カムパニー　インコーポレーテッド	肝炎ｃ型ウイルスコンジュゲート
US20030092145A1 (en) *	2000-08-24	2003-05-15	Vic Jira	Viral vaccine composition, process, and methods of use
US7033593B2 (en)	2000-09-22	2006-04-25	Duke University	Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CZ20031225A3 (cs)	2000-11-10	2003-10-15	Wyeth Holdings Corporation	Adjuvantní kombinované prostředky
US6906169B2 (en)	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20030224011A1 (en) *	2001-05-29	2003-12-04	Conley Anthony J	Hepatitis c virus conjugates
ATE451386T1 (de)	2001-06-07	2009-12-15	Wyeth Corp	Mutantenformen von cholera holotoxin als adjuvans
IL159209A0 (en)	2001-06-07	2004-06-01	Wyeth Corp	Mutant forms of cholera holotoxin as an adjuvant
US20030135035A1 (en) *	2001-08-09	2003-07-17	Mark Shannon	Human ZZAP1 protein
EP1572894B1 (en)	2001-11-21	2016-04-13	New York University	Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
ATE496917T1 (de)	2001-12-20	2011-02-15	Randox Lab Ltd	Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
FR2833840B1 (fr) *	2001-12-21	2010-06-18	Rytek	Methodes et compositions pour le traitement de pathologies respiratoires
AU2003231279A1 (en)	2002-04-30	2003-11-17	Wyeth Holdings Corporation	Prevention and treatment of type 2 diabetes
KR20050006275A (ko) *	2002-05-28	2005-01-15	코닌클리즈케 필립스 일렉트로닉스 엔.브이.	데이터 유닛 처리 방법, 수신기, 전송 시스템, 컴퓨터프로그램 및 신호
MXPA05006940A (es) *	2002-12-24	2006-02-22	Neurochem Int Ltd	Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
CA2517439C (en) *	2003-03-07	2013-07-23	Wyeth Holdings Corporation	Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) *	2003-03-17	2006-11-09	Michael Hagen	Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN100409896C (zh) *	2003-03-31	2008-08-13	姚志彬	一种老年性痴呆疫苗及其制备方法
EA012984B1 (ru)	2003-12-17	2010-02-26	Вайет	Конъюгаты иммуногенных пептидных носителей и способы их получения
AR047062A1 (es) *	2003-12-17	2006-01-04	Wyeth Corp	Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
JP5045349B2 (ja)	2007-10-01	2012-10-10	パナソニック株式会社	左手系フィルタ

2004
- 2004-12-17 AR ARP040104758A patent/AR047062A1/es not_active Application Discontinuation
- 2004-12-17 KR KR1020117020349A patent/KR101201120B1/ko not_active IP Right Cessation
- 2004-12-17 KR KR1020067014293A patent/KR101158147B1/ko not_active IP Right Cessation
- 2004-12-17 UA UAA200608020A patent/UA84728C2/ru unknown
- 2004-12-17 SI SI200432170T patent/SI2336147T1/sl unknown
- 2004-12-17 ES ES11151428.7T patent/ES2474173T3/es active Active
- 2004-12-17 EP EP11151428.7A patent/EP2336147B1/en active Active
- 2004-12-17 SG SG2012043139A patent/SG182189A1/en unknown
- 2004-12-17 EA EA200601168A patent/EA009559B1/ru not_active IP Right Cessation
- 2004-12-17 CA CA002549552A patent/CA2549552A1/en not_active Abandoned
- 2004-12-17 AU AU2004299512A patent/AU2004299512B2/en not_active Ceased
- 2004-12-17 TW TW093139610A patent/TWI357414B/zh not_active IP Right Cessation
- 2004-12-17 EP EP12157140A patent/EP2460813A1/en not_active Withdrawn
- 2004-12-17 DK DK11151428.7T patent/DK2336147T3/da active
- 2004-12-17 US US10/583,503 patent/US8227403B2/en not_active Expired - Fee Related
- 2004-12-17 TW TW100140530A patent/TWI379839B/zh not_active IP Right Cessation
- 2004-12-17 PT PT111514287T patent/PT2336147E/pt unknown
- 2004-12-17 EP EP04817081A patent/EP1699810A4/en not_active Withdrawn
- 2004-12-17 WO PCT/US2004/044093 patent/WO2005058941A2/en active Application Filing
- 2004-12-17 EA EA200702209A patent/EA011239B1/ru not_active IP Right Cessation
- 2004-12-17 MX MXPA06006821A patent/MXPA06006821A/es active IP Right Grant
- 2004-12-17 EP EP12157147.5A patent/EP2479184A3/en not_active Withdrawn
- 2004-12-17 JP JP2006545618A patent/JP4696079B2/ja not_active Expired - Fee Related
- 2004-12-17 BR BRPI0417689A patent/BRPI0417689A8/pt not_active IP Right Cessation
- 2004-12-17 PL PL11151428T patent/PL2336147T3/pl unknown
- 2004-12-17 SG SG200809362-7A patent/SG149039A1/en unknown
- 2004-12-17 CN CN200480041798.9A patent/CN1934127B/zh not_active Expired - Fee Related
- 2004-12-17 MY MYPI20045205A patent/MY144231A/en unknown
2006
- 2006-06-08 CR CR8445A patent/CR8445A/es unknown
- 2006-06-12 IL IL176250A patent/IL176250A/en not_active IP Right Cessation
- 2006-06-13 NO NO20062765A patent/NO20062765L/no not_active Application Discontinuation
- 2006-06-15 EC EC2006006646A patent/ECSP066646A/es unknown
2007
- 2007-08-20 US US11/841,993 patent/US20080299074A1/en not_active Abandoned
- 2007-08-20 US US11/841,919 patent/US9095536B2/en not_active Expired - Fee Related
- 2007-09-21 HK HK07110272.1A patent/HK1104826A1/xx not_active IP Right Cessation
2011
- 2011-02-24 AU AU2011200785A patent/AU2011200785B2/en not_active Ceased
- 2011-05-26 IL IL213156A patent/IL213156A/en not_active IP Right Cessation
- 2011-07-07 US US13/178,428 patent/US9089510B2/en not_active Expired - Fee Related
- 2011-11-14 HK HK11112264.1A patent/HK1157795A1/xx not_active IP Right Cessation
2012
- 2012-02-14 US US13/396,543 patent/US9125847B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2011200785A1 (en)	2011-03-17
TW201206956A (en)	2012-02-16
TW200533679A (en)	2005-10-16
EA200702209A1 (ru)	2008-02-28
IL176250A (en)	2011-11-30
CN1934127A (zh)	2007-03-21
IL213156A (en)	2014-05-28
EP2460813A1 (en)	2012-06-06
KR101201120B1 (ko)	2012-12-03
US8227403B2 (en)	2012-07-24
EP2479184A3 (en)	2013-09-04
HK1157795A1 (en)	2012-07-06
US9095536B2 (en)	2015-08-04
BRPI0417689A (pt)	2007-04-03
MY144231A (en)	2011-08-15
TWI357414B (en)	2012-02-01
KR20070026363A (ko)	2007-03-08
CA2549552A1 (en)	2005-06-30
AU2004299512B2 (en)	2010-11-25
EP2479184A2 (en)	2012-07-25
US20070161088A1 (en)	2007-07-12
EP2336147B1 (en)	2014-04-30
SI2336147T1 (sl)	2014-08-29
UA84728C2 (ru)	2008-11-25
EP1699810A2 (en)	2006-09-13
AU2004299512A1 (en)	2005-06-30
US9089510B2 (en)	2015-07-28
KR20110117210A (ko)	2011-10-26
MXPA06006821A (es)	2006-08-23
CN1934127B (zh)	2015-08-19
EA009559B1 (ru)	2008-02-28
KR101158147B1 (ko)	2012-07-17
US20080299074A1 (en)	2008-12-04
AU2011200785B2 (en)	2012-12-06
PL2336147T3 (pl)	2015-01-30
EA200601168A1 (ru)	2006-12-29
CR8445A (es)	2008-02-20
SG149039A1 (en)	2009-01-29
BRPI0417689A8 (pt)	2017-04-25
IL176250A0 (en)	2006-10-05
EP2336147A2 (en)	2011-06-22
WO2005058941A3 (en)	2006-06-01
TWI379839B (en)	2012-12-21
AR047062A1 (es)	2006-01-04
PT2336147E (pt)	2014-07-16
US20110287042A1 (en)	2011-11-24
EA011239B1 (ru)	2009-02-27
EP1699810A4 (en)	2009-10-21
EP2336147A3 (en)	2011-07-27
ES2474173T3 (es)	2014-07-08
JP4696079B2 (ja)	2011-06-08
ECSP066646A (es)	2006-12-20
HK1104826A1 (en)	2008-01-25
DK2336147T3 (da)	2014-06-10
SG182189A1 (en)	2012-07-30
US20080145373A1 (en)	2008-06-19
WO2005058941A2 (en)	2005-06-30
IL213156A0 (en)	2011-07-31
US9125847B2 (en)	2015-09-08
JP2007534650A (ja)	2007-11-29
US20120207706A1 (en)	2012-08-16

Publication	Publication Date	Title
NO20062765L (no)	2006-09-14	Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse
WO2005058940A3 (en)	2006-10-26	Immunogenic peptide carrier conjugates and methods of producing same
EP2925368B1 (en)	2019-03-27	Methods for making conjugates from disulfide-containing proteins
Pechar et al.	2002	Associative diblock copolymers of poly (ethylene glycol) and coiled‐coil peptides
Lagnoux et al.	2005	Inhibition of mitosis by glycopeptide dendrimer conjugates of colchicine
BRPI0417341A (pt)	2007-04-17	fator ix glicopeguilado
NO20080970L (no)	2008-05-19	Glykopegylert faktor VII og faktor VIIA
NO20043891L (no)	2004-09-16	Anti-A-beta-antistoffer og deres anvendelse
Nawroth et al.	2016	Maleimide‐Functionalized Poly (2‐Oxazoline) s and Their Conjugation to Elastin‐Like Polypeptides
Katayama et al.	2011	Chemical synthesis of the S‐linked glycopeptide, sublancin
Tsukagoshi et al.	2020	Basic Amino Acid Conjugates of 1, 2‐Diselenan‐4‐amine with Protein Disulfide Isomerase‐like Functions as a Manipulator of Protein Quality Control
Grandjean et al.	2001	Synthesis of Clustered Glycoside–Antigen Conjugates by Two One‐Pot, Orthogonal, Chemoselective Ligation Reactions: Scope and Limitations
Kadereit et al.	2001	Acid‐labile protecting groups for the synthesis of lipidated peptides
Mezö et al.	2003	Synthesis and Comparison of Antibody Recognition of Conjugates Containing Herpes Simplex Virus Type 1 Glycoprotein D Epitope VII1
Kantchev et al.	2006	Direct Fmoc/tert‐Bu solid phase synthesis of octamannosyl polylysine dendrimer–peptide conjugates
EP0468714A2 (en)	1992-01-29	Peptide-polysaccharide-protein conjugate vaccines
Baigude et al.	2004	Synthesis of structurally‐controlled AIDS vaccine model with glyco‐peptide dendrimer scaffolds
Uray et al.	2014	The effect of glycosylation on the antibody recognition of a MUC2 mucin epitope
Euzen et al.	2011	Synthesis of glycopeptide dendrimers, dimerization and affinity for Concanavalin A
Pillai et al.	2006	A flexible method for preparation of peptide homo‐and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups
Bodero et al.	2021	Synthesis and Biological Evaluation of an isoDGR‐Paclitaxel Conjugate Containing a Cell‐Penetrating Peptide to Promote Cellular Uptake
Cobo et al.	2022	Probing Site‐Selective Conjugation Chemistries for the Construction of Homogeneous Synthetic Glycodendriproteins
TH115317B (th)	2012-07-31	A(สูตร) อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้
Zeppezauer et al.	1993	Hydrophilic Polystyrene-Polyoxyethylene Graft Polymer Beads as Carrier of Antigenic Peptides for in vivo and in vitro Immunization Techniques: Applications to the Non-Catalytic Zinc Loop of HLADH Isozymes and to Histone Fragments
TH115317A (th)	2012-07-31	Ab อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้

Legal Events

Date	Code	Title	Description
2018-07-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application